High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivomacrophage-to-feces reverse cholesterol transport in hamsters

Journal of Nutrition

Volumn 142, Issue 4, 2012, Pages 704-709

  Briand, François ^a   Thiéblemont, Quentin ^a   Muzotte, Elodie ^a   Sulpice, Thierry ^a  

^a Physiogenex SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DEOXYCHOLIC ACID; DRINKING WATER; FAT; FRUCTOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIETARY INTAKE; DYSLIPIDEMIA; FATTY LIVER; FECES; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HAMSTER; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE ABSORPTION; LIPID DIET; MACROPHAGE; MALE; METABOLIC DISORDER; NONHUMAN; REVERSE CHOLESTEROL TRANSPORT; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; KINETICS; LIVER; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; SYRIAN HAMSTER; TRANSPORT AT THE CELLULAR LEVEL; UPREGULATION;

CRICETINAE; MESOCRICETUS AURATUS;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FATTY LIVER; FECES; FRUCTOSE; INSULIN RESISTANCE; KINETICS; LIVER; MACROPHAGES; MALE; MESOCRICETUS; METABOLIC SYNDROME X; TRIGLYCERIDES; UP-REGULATION;

EID: 84861174179     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.153197     Document Type: Article

References (37)

1. Astrup A, Dyerberg J, Selleck M, Stender S. Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes Rev. 2008;9 Suppl 1:48-52.
2. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008; 93(11, Suppl 1):S9-30.
3. Misra A, Singhal N, Khurana L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils. J Am Coll Nutr. 2010; 29 Suppl 3:S289-301.
4. Tappy L, Lê KA.Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23-46.
5. Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci. 2010;1212:29-40.
6. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113:2548-55.
7. Miller NE, La Ville A, Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature. 1985;314:109-11.
8. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-9.
9. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol. 2006;17:28-36.
10. Escolà-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophagespecific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis. 2009;206:321-7.
11. Briand F. The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport. Curr Opin Investig Drugs. 2010;11:289-97.
12. Briand F, Tréguier M, André A, Grillot D, Issandou M, Ouguerram K, Sulpice T. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res. 2010;51:763-70.
13. Tréguier M, Briand F, Boubacar A, André A, Magot T, Nguyen P, Krempf M, Sulpice T, Ouguerram K. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters. Eur J Clin Invest. 2011;41:921-8.
14. Wang PR, Guo Q, Ippolito M, Wu M, Milot D, Ventre J, Doebber T, Wright SD, Chao YS. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur J Pharmacol. 2001;427:285-93.
15. Duan LP, Wang HH, Ohashi A, Wang DQ. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol. 2006;290:G269-76.
16. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res. 2004;45:1410-7.
17. Briand F, Naik SU, Fuki I, Millar JS, Macphee C, Walker M, Billheimer J, Rothblat G, Rader DJ. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci. 2009;2:127-33.
18. Sulpice T, Prunet-Marcassus B, Molveaux C, Cani PD, Vitte PA, Graber P, Dreano M, Burcelin R. An adiponectin-like molecule with antidiabetic properties. Endocrinology. 2009;150:4493-501.
19. Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International. 2004;11:36-42.
20. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O'Keefe JH, Brand-Miller J. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005;81:341-54.
21. Wu JY, Reaves SK, Wang YR, Wu Y, Lei PP, Lei KY. Zinc deficiency decreases plasma level and hepatic mRNA abundance of apolipoprotein A-I in rats and hamsters. Am J Physiol. 1998;275:C1516-25.
22. Lei KY. Dietary copper: cholesterol and lipoprotein metabolism. Annu Rev Nutr. 1991;11:265-83.
23. Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease?World J Gastrointest Pharmacol Ther. 2011;2:1-5.
24. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-64.
25. Izem L, Morton RE. Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia. J Lipid Res. 2009;50:676-84.
26. Woollett LA, Spady DK, Dietschy JM. Mechanisms by which saturated triacylglycerols elevate the plasma low density lipoprotein-cholesterol concentration in hamsters. Differential effects of fatty acid chain length. J Clin Invest. 1989;84:119-28.
27. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem. 2003;278:48275-82.
28. Vrins CL. From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux. World J Gastroenterol. 2010;16:5953-7.
29. Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol. 2011;31:1726-33.
30. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 2011;140:1043-51.
31. van der Veen JN, van Dijk TH, Vrins CL, van Meer H, Havinga R, Bijsterveld K, Tietge UJ, Groen AK, Kuipers F. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem. 2009;284:19211-9.
32. van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK. Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295:G203-8.
33. Brown JM, Bell TA III, Alger HM, Sawyer JK, Smith TL, Kelley K, Shah R, Wilson MD, Davis MA, Lee RG, et al. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J Biol Chem. 2008;283:10522-34.
34. Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009;104:82-91.
35. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, et al.. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-15.
36. Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77:732-9.
37. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-b-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443-54.